Gilead Sciences, Inc. (NASDAQ:GILD) Receives $110.55 Average Target Price from Brokerages

Shares of Gilead Sciences, Inc. (NASDAQ:GILD) have received an average rating of “Moderate Buy” from the twenty-seven ratings firms that are covering the stock, Marketbeat reports. Nine research analysts have rated the stock with a hold recommendation, fifteen have given a buy recommendation and three have given a strong buy recommendation to the company. The average 12-month target price among analysts that have issued ratings on the stock in the last year is $110.55.

GILD has been the subject of several analyst reports. BMO Capital Markets increased their target price on shares of Gilead Sciences from $110.00 to $115.00 and gave the company an “outperform” rating in a report on Wednesday, February 12th. Morgan Stanley increased their price objective on shares of Gilead Sciences from $130.00 to $135.00 and gave the company an “overweight” rating in a research note on Friday, April 25th. JPMorgan Chase & Co. increased their price objective on shares of Gilead Sciences from $120.00 to $130.00 and gave the company an “overweight” rating in a research note on Thursday, March 27th. DZ Bank upgraded shares of Gilead Sciences from a “hold” rating to a “buy” rating and set a $108.00 price objective for the company in a research note on Thursday, February 13th. Finally, Wells Fargo & Company increased their price target on Gilead Sciences from $120.00 to $140.00 and gave the company an “overweight” rating in a research report on Wednesday, March 5th.

Insider Activity at Gilead Sciences

In related news, CFO Andrew D. Dickinson sold 2,500 shares of the business’s stock in a transaction dated Thursday, May 15th. The stock was sold at an average price of $99.82, for a total transaction of $249,550.00. Following the completion of the transaction, the chief financial officer now directly owns 165,674 shares in the company, valued at $16,537,578.68. The trade was a 1.49% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Johanna Mercier sold 28,000 shares of the business’s stock in a transaction dated Thursday, May 22nd. The stock was sold at an average price of $107.52, for a total value of $3,010,560.00. Following the transaction, the insider now owns 121,152 shares of the company’s stock, valued at approximately $13,026,263.04. The trade was a 18.77% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 43,000 shares of company stock worth $4,630,310. Corporate insiders own 0.27% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the business. Smallwood Wealth Investment Management LLC purchased a new position in Gilead Sciences in the 1st quarter worth approximately $25,000. Activest Wealth Management grew its position in Gilead Sciences by 2,837.5% in the first quarter. Activest Wealth Management now owns 235 shares of the biopharmaceutical company’s stock worth $26,000 after acquiring an additional 227 shares in the last quarter. Goodman Advisory Group LLC purchased a new position in Gilead Sciences in the first quarter worth $29,000. Colonial Trust Advisors grew its position in Gilead Sciences by 304.3% in the first quarter. Colonial Trust Advisors now owns 283 shares of the biopharmaceutical company’s stock worth $32,000 after acquiring an additional 213 shares in the last quarter. Finally, Newbridge Financial Services Group Inc. purchased a new position in shares of Gilead Sciences in the 4th quarter worth about $33,000. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Gilead Sciences Trading Down 2.6%

GILD opened at $110.09 on Friday. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.50 and a quick ratio of 1.20. Gilead Sciences has a fifty-two week low of $62.69 and a fifty-two week high of $119.96. The firm has a market capitalization of $136.94 billion, a PE ratio of 297.54, a P/E/G ratio of 0.71 and a beta of 0.29. The company’s 50-day moving average is $105.36 and its 200 day moving average is $101.86.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Thursday, April 24th. The biopharmaceutical company reported $1.81 EPS for the quarter, topping the consensus estimate of $1.77 by $0.04. The firm had revenue of $6.67 billion during the quarter, compared to the consensus estimate of $6.77 billion. Gilead Sciences had a return on equity of 31.63% and a net margin of 1.67%. The company’s quarterly revenue was down .3% compared to the same quarter last year. During the same period in the prior year, the business posted ($1.32) earnings per share. As a group, research analysts predict that Gilead Sciences will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, June 27th. Investors of record on Friday, June 13th will be paid a $0.79 dividend. The ex-dividend date is Friday, June 13th. This represents a $3.16 dividend on an annualized basis and a yield of 2.87%. Gilead Sciences’s dividend payout ratio is 66.53%.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.